Skip to main content

Table 1 Characteristics of randomized controlled trials of vitamin D supplementation on IBS

From: The efficacy of vitamin D supplementation for irritable bowel syndrome: a systematic review with meta-analysis

Study Country Study design IBS criteria Case Control Vitamin D dose Treatment duration Primary outcomes Secondary outcomes
(n) (n)
Abbasnezhad 2016 [23] Iran Double-blind IBS-C 34.1%, IBS-D 25.9%, IBS-A 40% 44 41 50000 IU VD3 fortnightly 6 months IBS-SSS IBS-QoL, the measurement of GI symptoms
Khalighi Sikaroudi 2020 [24] Iran Double-blind IBS-D 44 44 50000 IU VD3 weekly 9 weeks IBS-SSS IL-6, CRH
El Amrousy 2018 [25] Egypt Double-blind IBS-C 61.8%, IBS-D 18.6%, IBS-M 10.8%, IBS-U 8.9% 56 56 2000 IU VD3 daily 6 months IBS-SSS IBS-QoL, IBS-TS
Jalili 2016 [26] Iran Double-blind all subtypes (the proportion of each subtype was unclear) 25 25 50000 IU VD3 fortnightly 6 weeks IBS-SSS IBS-TS
  1. IBS irritable bowel syndrome, IBS-C, -D, -A, -M, -U IBS with predominant constipation, predominant diarrhea, predominant alternating bowel habit, mixed and unsubtyped, IBS-QoL IBS-quality of life, IBS-SSS IBS-severity scoring system, IBS-TS IBS-total score, IU international unit, VD3 vitamin D3